On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.
On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.
Key facts
Extracted from this filing and checked against the source text.
Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
market value
Rules
5550(b)(2)
Exact text from the filing
January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecu
Ernexa Therapeutics Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).
Exchange
nasdaq
Notice
deficiency notice
Deficiency
market value
Rules
5550(b)(2), 5810(c)(3)(C)
Exact text from the filing
January 6, 2025, Eterna Therapeutics Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that for the last 35 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “Market Value Standard”). Nasdaq Listing Rule 5810(c)(3)(C) provides a compliance period of 180 calendar days, or until July 7, 2025, in which to regain compl
Elena Ratner was appointed as Director at Ernexa Therapeutics Inc..
Action
appointed
Role
Director
Exact text from the filing
On January 6, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Dr. Elena Ratner to the Board effective January 7, 2025.
Dorothy Clarke resigned as Director at Ernexa Therapeutics Inc..
Action
resigned
Role
Director
Exact text from the filing
On January 3, 2025, Dorothy Clarke submitted her resignation from the Board of Directors (the “ Board ”) of the Company, effective at 11:59 p.m. Eastern Time on January 6, 2025.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.